{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:37:45Z","timestamp":1791265065592,"version":"4.1.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,2,1]]},"DOI":"10.1093\/jac\/dkh531","type":"journal-article","created":{"date-parts":[[2005,1,20]],"date-time":"2005-01-20T01:24:30Z","timestamp":1106184270000},"page":"240-245","source":"Crossref","is-referenced-by-count":143,"title":["Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections"],"prefix":"10.1093","volume":"55","author":[{"given":"Benjamin A.","family":"Lipsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uschi","family":"Stoutenburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,2]]},"reference":[{"key":"key\n\t\t\t\t20171013041452_R1","doi-asserted-by":"crossref","unstructured":"Lipsky, B. A. (2004). A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes\/Metabolism Research and Reviews20, Suppl. 1, S68\u2013S77.","DOI":"10.1002\/dmrr.453"},{"key":"key\n\t\t\t\t20171013041452_R2","doi-asserted-by":"crossref","unstructured":"Lipsky, B. A., Berendt, A. R., Deery, H. G. et al. (2004). Diagnosis and treatment of diabetic foot infections. Clinical Infectious Diseases39, 885\u2013910.","DOI":"10.1086\/424846"},{"key":"key\n\t\t\t\t20171013041452_R3","doi-asserted-by":"crossref","unstructured":"Lipsky, B. A., Pecoraro, R. E., Larson, S. A. et al. (1990). Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Archives of Internal Medicine150, 790\u20137.","DOI":"10.1001\/archinte.1990.00390160058013"},{"key":"key\n\t\t\t\t20171013041452_R4","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. (1999). Consensus Development Conference on Diabetic Foot Wound Care: 7\u20138 April 1999, Boston, Massachusetts. Diabetes Care22, 1354\u201360.","DOI":"10.2337\/diacare.22.8.1354"},{"key":"key\n\t\t\t\t20171013041452_R5","doi-asserted-by":"crossref","unstructured":"Lipsky, B. A., Pecoraro, R. E. & Wheat, L. J. (1990). The diabetic foot. Soft tissue and bone infection. Infectious Disease Clinics of North America4, 409\u201332.","DOI":"10.1016\/S0891-5520(20)30354-8"},{"key":"key\n\t\t\t\t20171013041452_R6","unstructured":"Lipsky, B. A. (2001). Diabetic foot infections: progress in a pedestrian problem. Contemporary Surgery57, S7\u2013S19."},{"key":"key\n\t\t\t\t20171013041452_R7","doi-asserted-by":"crossref","unstructured":"Lipsky, B. A., Itani, K. & Norden, C. (2004). Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam\/co-amoxiclav. Clinical Infectious Diseases38, 17\u201324.","DOI":"10.1086\/380449"},{"key":"key\n\t\t\t\t20171013041452_R8","doi-asserted-by":"crossref","unstructured":"NNIS. (2003). National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. American Journal of Infection Control31, 481\u201398.","DOI":"10.1016\/j.ajic.2003.09.002"},{"key":"key\n\t\t\t\t20171013041452_R9","doi-asserted-by":"crossref","unstructured":"Eady, E. A. & Cove, J. H. (2003). Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus\u2014an emerging problem for the management of skin and soft tissue infections. Current Opinion in Infectious Diseases16, 103\u201324.","DOI":"10.1097\/00001432-200304000-00007"},{"key":"key\n\t\t\t\t20171013041452_R10","doi-asserted-by":"crossref","unstructured":"Naimi, T. S., LeDell, K. H., Como-Sabetti, K. et al. (2003). Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. Journal of the American Medical Association290, 2976\u201384.","DOI":"10.1001\/jama.290.22.2976"},{"key":"key\n\t\t\t\t20171013041452_R11","doi-asserted-by":"crossref","unstructured":"Dang, C. N., Prasad, Y. D., Boulton, A. J. et al. (2003). Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabetic Medicine20, 159\u201361.","DOI":"10.1046\/j.1464-5491.2003.00860.x"},{"key":"key\n\t\t\t\t20171013041452_R12","unstructured":"Fejfarova, V., Jirkovska, A., Skibova, J. et al. (2002). Pathogen resistance and other risk factors in the frequency of lower limb amputations in patients with the diabetic foot syndrome. Vnitrni Lekarstvi48, 302\u20136."},{"key":"key\n\t\t\t\t20171013041452_R13","doi-asserted-by":"crossref","unstructured":"Tentolouris, N., Jude, E. B., Smirnof, I. et al. (1999). Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabetic Medicine16, 767\u201371.","DOI":"10.1046\/j.1464-5491.1999.00132.x"},{"key":"key\n\t\t\t\t20171013041452_R14","unstructured":"Mantey, I., Hill, R. L., Foster, A. V. et al. (2000). Infection of foot ulcers with Staphylococcus aureus associated with increased mortality in diabetic patients. Communicable Disease and Public Health\/PHLS3, 288\u201390."},{"key":"key\n\t\t\t\t20171013041452_R15","doi-asserted-by":"crossref","unstructured":"Wagner, A., Reike, H. & Angelkort, B. (2001). Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant Staphylococcus aureus infections. Deutsche Medizinische Wochenschrift126, 1353\u20136.","DOI":"10.1055\/s-2001-18655"},{"key":"key\n\t\t\t\t20171013041452_R16","doi-asserted-by":"crossref","unstructured":"Carpenter, C. F. & Chambers, H. F. (2004). Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clinical Infectious Diseases38, 994\u20131000.","DOI":"10.1086\/383472"},{"key":"key\n\t\t\t\t20171013041452_R17","doi-asserted-by":"crossref","unstructured":"Cha, R., Brown, W. J. & Rybak, M. J. (2003). Bactericidal activities of daptomycin, quinupristin\u2013dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrobial Agents and Chemotherapy47, 3960\u20133.","DOI":"10.1128\/AAC.47.12.3960-3963.2003"},{"key":"key\n\t\t\t\t20171013041452_R18","doi-asserted-by":"crossref","unstructured":"Fluit, A. C., Schmitz, F. J., Verhoef, J. et al. (2004). In vitro activity of daptomycin against Gram-positive European clinical isolates with defined resistance determinants. Antimicrobial Agents and Chemotherapy48, 1007\u201311.","DOI":"10.1128\/AAC.48.3.1007-1011.2004"},{"key":"key\n\t\t\t\t20171013041452_R19","doi-asserted-by":"crossref","unstructured":"Streit, J. M., Jones, R. N. & Sader, H. S. (2004). Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. Journal of Antimicrobial Chemotherapy53, 669\u201374.","DOI":"10.1093\/jac\/dkh143"},{"key":"key\n\t\t\t\t20171013041452_R20","doi-asserted-by":"crossref","unstructured":"Arbeit, R. D., Maki, D., Tally, F. P. et al. (2004). The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clinical Infectious Diseases38, 1673\u201381.","DOI":"10.1086\/420818"},{"key":"key\n\t\t\t\t20171013041452_R21","unstructured":"National Committee for Clinical Laboratory Standards. (1997). Performance Standards for Antimicrobial Disk Susceptibility Tests\u2014Sixth Edition: Approved Standard M2-A6. NCCLS, Villanova, PA, USA."},{"key":"key\n\t\t\t\t20171013041452_R22","unstructured":"Murray, P. R., Baron, E. J., Jorgensen, J. H., et al. (2004). Manual of Clinical Microbiology, 6th edn. ASM Press, Washington, DC, USA."},{"key":"key\n\t\t\t\t20171013041452_R23","unstructured":"National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically\u2014Fourth Edition: Approved Standard M7-A4. NCCLS, Villanova, PA, USA."},{"key":"key\n\t\t\t\t20171013041452_R24","unstructured":"National Committee for Clinical Laboratory Standards. (2000). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically\u2014Fifth Edition: Approved Standard M7-A5. NCCLS, Villanova, PA, USA."},{"key":"key\n\t\t\t\t20171013041452_R25","unstructured":"Food and Drug Administration. (2004). MedDRA: medical dictionary for regulatory activities. [Online.] http:\/\/www.fda.gov\/medwatch\/report\/meddra.htm (20 August 2004, date last accessed)."},{"key":"key\n\t\t\t\t20171013041452_R26","unstructured":"Food and Drug Administration. (1996). Guideline for Industry: Structure and Content of Clinical Study Reports. Food and Drug Administration, Rockville, MD, USA."},{"key":"key\n\t\t\t\t20171013041452_R27","doi-asserted-by":"crossref","unstructured":"Hauck, W. & Anderson, S. (1986). A comparison of large sample confidence interval methods for the difference of two binomial probabilities. American Statistician40, 318\u201322.","DOI":"10.1080\/00031305.1986.10475426"},{"key":"key\n\t\t\t\t20171013041452_R28","doi-asserted-by":"crossref","unstructured":"Lipsky, B. A. (1999). Evidence-based antibiotic therapy of diabetic foot infections. FEMS Immunology and Medical Microbiology26, 267\u201376.","DOI":"10.1111\/j.1574-695X.1999.tb01398.x"},{"key":"key\n\t\t\t\t20171013041452_R29","doi-asserted-by":"crossref","unstructured":"Kirby, W. M. (1984). Vancomycin therapy of severe staphylococcal infections. Journal of Antimicrobial Chemotherapy14, Suppl. D, 73\u20138.","DOI":"10.1093\/jac\/14.suppl_D.73"},{"key":"key\n\t\t\t\t20171013041452_R30","doi-asserted-by":"crossref","unstructured":"Shah, N. P., Reddy, P., Paladino, J. A. et al. (2004). Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model. Current Medical Research and Opinion20, 779\u201390.","DOI":"10.1185\/030079904125003638"},{"key":"key\n\t\t\t\t20171013041452_R31","doi-asserted-by":"crossref","unstructured":"Levine, D. P., Fromm, B. S. & Reddy, B. R. (1991). Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Annals of Internal Medicine115, 674\u201380.","DOI":"10.7326\/0003-4819-115-9-674"},{"key":"key\n\t\t\t\t20171013041452_R32","doi-asserted-by":"crossref","unstructured":"Diekema, D. J., BootsMiller, B. J., Vaughn, T. E. et al. (2004). Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clinical Infectious Diseases38, 78\u201385.","DOI":"10.1086\/380457"},{"key":"key\n\t\t\t\t20171013041452_R33","unstructured":"Miller, D., Urdaneta, V. & Weltman, A. (2002). Vancomycin-resistant Staphylococcus aureus\u2014Pennsylvania, 2002. MMWR Morbidity and Mortality Weekly Report51, 902."},{"key":"key\n\t\t\t\t20171013041452_R34","unstructured":"Centers for Disease Control and Prevention. (1995). Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Morbidity and Mortality Weekly Report Recommendations and Reports 44, 1\u201313."},{"key":"key\n\t\t\t\t20171013041452_R35","doi-asserted-by":"crossref","unstructured":"Vinken, A. G., Li, J. Z., Balan, D. A. et al. (2003). Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals. American Journal of Therapeutics10, 264\u201374.","DOI":"10.1097\/00045391-200307000-00006"},{"key":"key\n\t\t\t\t20171013041452_R36","doi-asserted-by":"crossref","unstructured":"Li, J. Z., Willke, R. J., Rittenhouse, B. E. et al. (2003). Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surgical Infections4, 57\u201370.","DOI":"10.1089\/109629603764655290"},{"key":"key\n\t\t\t\t20171013041452_R37","doi-asserted-by":"crossref","unstructured":"Rubinstein, E., Isturiz, R., Standiford, H. C. et al. (2003). Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrobial Agents and Chemotherapy47, 1824\u201331.","DOI":"10.1128\/AAC.47.6.1824-1831.2003"},{"key":"key\n\t\t\t\t20171013041452_R38","doi-asserted-by":"crossref","unstructured":"Kuter, D. J. & Tillotson, G. S. (2001). Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy21, 1010\u20133.","DOI":"10.1592\/phco.21.11.1010.34517"},{"key":"key\n\t\t\t\t20171013041452_R39","doi-asserted-by":"crossref","unstructured":"Ruiz, M. E., Guerrero, I. C. & Tuazon, C. U. (2002). Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clinical Infectious Diseases35, 1018\u201320.","DOI":"10.1086\/342698"},{"key":"key\n\t\t\t\t20171013041452_R40","doi-asserted-by":"crossref","unstructured":"Sperber, S. J., Levine, J. F. & Gross, P. A. (2003). Persistent MRSA bacteremia in a patient with low linezolid levels: correspondence. Clinical Infectious Diseases36, 675\u20136.","DOI":"10.1086\/367671"},{"key":"key\n\t\t\t\t20171013041452_R41","doi-asserted-by":"crossref","unstructured":"Silverman, J. A., Perlmutter, N. G. & Shapiro, H. M. (2003). Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy47, 2538\u201344.","DOI":"10.1128\/AAC.47.8.2538-2544.2003"},{"key":"key\n\t\t\t\t20171013041452_R42","doi-asserted-by":"crossref","unstructured":"Rybak, M. J., Hershberger, E., Moldovan, T. et al. (2000). In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin\u2013dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrobial Agents and Chemotherapy44, 1062\u20136.","DOI":"10.1128\/AAC.44.4.1062-1066.2000"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/55\/2\/240\/2544560\/dkh531.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T18:30:00Z","timestamp":1734892200000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/55\/2\/240\/856804\/Daptomycin-for-treating-infected-diabetic-foot"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,1]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,2]]},"published-print":{"date-parts":[[2005,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkh531","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,2]]},"published":{"date-parts":[[2005,2,1]]}}}